Dapsone with Padagis?, page-2

I'd be pleased if Padagis is our partner with Dapsone 5% & 7.5%. 5% yearly sales US$17 to 19 million in yearly sales. 7.5% US$206 million in yearly sales. Dapsone 7.5% when launched will be our biggest market for any of our products. Also I don't think Padagis would bother with a drug with low potential. Would love to know what the product is that ACR were working with Amring on. A US$400 million market, I wonder if that is still on track? As for Jublia, the drug that was supposed to launch ACR into the US Generic Market, with yearly sales of US$292 million has had approval for years now but still not launched. Jet